Access cutting-edge thyroid cancer treatment through this clinical trial at a research site in Hartford. Study-provided care at no cost to qualified participants.
Access thyroid cancer specialists in Hartford at no cost
This study follows strict safety protocols and ethical guidelines
All study-related thyroid cancer treatment provided free
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth
Sponsor: ECOG-ACRIN Cancer Research Group
Check if you qualify for this thyroid cancer clinical trial in Hartford, CT
If you're searching for thyroid cancer treatment options in Hartford, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Hartford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced thyroid cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.